Cargando…
Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
BACKGROUND: High-dose IL-2 (HDIL2) is approved for the treatment of metastatic melanoma and renal cell carcinoma, but its use is limited in part by toxicity related to the development of vascular leak syndrome (VLS). Therefore, an understanding of the mechanisms that underlie the initiation and prog...
Autores principales: | Kim, Dae Won, Zloza, Andrew, Broucek, Joseph, Schenkel, Jason M, Ruby, Carl, Samaha, Georges, Kaufman, Howard L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062649/ https://www.ncbi.nlm.nih.gov/pubmed/24885155 http://dx.doi.org/10.1186/1479-5876-12-113 |
Ejemplares similares
-
Gene expression analysis of embryonic stem cells expressing VE-cadherin (CD144) during endothelial differentiation
por: Nikolova-Krstevski, Vesna, et al.
Publicado: (2008) -
Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015) -
Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013) -
Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014) -
Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)